Head-to-head evidence
DA-302168S vs enicepatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
DA-302168S
Developed by Chendu DIAO Pharmaceutical Group
NCT06953063 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and enrolled 250 participants, with percentage change in body weight as a clinical primary endpoint. However, results are not posted, so it is not possible to determine whether the primary comparison was met; the available evidence therefore supports a moderate grade rather than a strong one.
Next expected readout: July 2027 · NCT07629544 (registry estimate)
enicepatide
Developed by Roche
NCT06525935 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: DA-302168S's landscape · enicepatide's landscape